dual inhibitors of CDK4/6 and FLT3 (Amgen)

N/A

Report date: 2025/03/19 11:37:36
NME

Base Information

Drug Namedual inhibitors of CDK4/6 and FLT3 (Amgen)
Drug Alias Namedual cyclin dependent kinase 4/6/FLT3 inhibitors (Amgen)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsCyclin-dependent kinase 6 inhibitors
TargetsCyclin-dependent kinase 6Tyrosine-protein kinase receptor FLT3Cyclin-dependent kinase 4
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A